Skip to main content
Journal cover image

Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.

Publication ,  Journal Article
Raber, MN; Faintuch, J; Abbruzzese, JL; Sumrall, C; Frost, P
Published in: Ann Oncol
July 1991

We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin. Of the thirty-six evaluable patients (21 adenocarcinoma, 14 undifferentiated carcinoma and 1 squamous cell carcinoma), eight patients responded to this treatment (4 CR, 4 PR). Responses were seen in both soft tissue and visceral disease. Toxicity was significant and included grade III/IV myelosuppression in over 90% of patients treated. Non-hematologic toxicity included nausea/vomiting and stomatitis. Although the remissions obtained in this study appear to be durable (median duration of complete remission greater than 24 months), the regimen does not appear to offer significant advantages over other less toxic and more easily administered cisplatin-based combinations.

Duke Scholars

Published In

Ann Oncol

DOI

ISSN

0923-7534

Publication Date

July 1991

Volume

2

Issue

7

Start / End Page

519 / 520

Location

England

Related Subject Headings

  • Survival Rate
  • Remission Induction
  • Oncology & Carcinogenesis
  • Neoplasms, Unknown Primary
  • Middle Aged
  • Humans
  • Fluorouracil
  • Etoposide
  • Drug Evaluation
  • Cisplatin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Raber, M. N., Faintuch, J., Abbruzzese, J. L., Sumrall, C., & Frost, P. (1991). Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. Ann Oncol, 2(7), 519–520. https://doi.org/10.1093/oxfordjournals.annonc.a058007
Raber, M. N., J. Faintuch, J. L. Abbruzzese, C. Sumrall, and P. Frost. “Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.Ann Oncol 2, no. 7 (July 1991): 519–20. https://doi.org/10.1093/oxfordjournals.annonc.a058007.
Raber, M. N., et al. “Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.Ann Oncol, vol. 2, no. 7, July 1991, pp. 519–20. Pubmed, doi:10.1093/oxfordjournals.annonc.a058007.
Journal cover image

Published In

Ann Oncol

DOI

ISSN

0923-7534

Publication Date

July 1991

Volume

2

Issue

7

Start / End Page

519 / 520

Location

England

Related Subject Headings

  • Survival Rate
  • Remission Induction
  • Oncology & Carcinogenesis
  • Neoplasms, Unknown Primary
  • Middle Aged
  • Humans
  • Fluorouracil
  • Etoposide
  • Drug Evaluation
  • Cisplatin